3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Carcinoma
2
Thoracic Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
34
pembrolizumab
27
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts